pCCL-c-MNDU3-X Citations (3)

Originally described in: Factors influencing the titer and infectivity of lentiviral vectors.
Logan AC, Nightingale SJ, Haas DL, Cho GJ, Pepper KA, Kohn DB Hum Gene Ther. 2004 Oct;15(10):976-88. PubMed Journal

---

Articles Citing pCCL-c-MNDU3-X

Articles
Lentiviral Gene Therapy in HSCs Restores Lineage-Specific Foxp3 Expression and Suppresses Autoimmunity in a Mouse Model of IPEX Syndrome. Masiuk KE, Laborada J, Roncarolo MG, Hollis RP, Kohn DB. Cell Stem Cell. 2019 Feb 7;24(2):309-317.e7. doi: 10.1016/j.stem.2018.12.003. Epub 2019 Jan 10. PubMed
Clonal transcriptomics identifies mechanisms of chemoresistance and empowers rational design of combination therapies. Wild SA, Cannell IG, Nicholls A, Kania K, Bressan D, Hannon GJ, Sawicka K. Elife. 2022 Dec 16;11:e80981. doi: 10.7554/eLife.80981. PubMed
Targeting advanced prostate cancer with STEAP1 chimeric antigen receptor T cell and tumor-localized IL-12 immunotherapy. Bhatia V, Kamat NV, Pariva TE, Wu LT, Tsao A, Sasaki K, Sun H, Javier G, Nutt S, Coleman I, Hitchcock L, Zhang A, Rudoy D, Gulati R, Patel RA, Roudier MP, True LD, Srivastava S, Morrissey CM, Haffner MC, Nelson PS, Priceman SJ, Ishihara J, Lee JK. Nat Commun. 2023 Apr 11;14(1):2041. doi: 10.1038/s41467-023-37874-2. PubMed

If you have published an article using this material, please email us at to have your article added to this page.